Acerus Pharma Revenue, Profits - TRLPF Quarterly Income Statement

Add to My Stocks
$0.21 $0 (0%) TRLPF stock closing price Sep 19, 2018 (Closing)

TRLPF stock valuation based on fundamental analysis involves checking and analyzing financial statements and not just the Acerus Pharma stock price. The key financial statements of a company are the income statement, the balance sheet and the cash flow statement. The income statement is generated for a specific period of time, typically a year or a quarter. The revenue increase to $2.1M for 2018 Q2 impacts the TRLPF stock. Investors typically check year over year or quarter over quarter revenue growth. One also needs to look at Acerus Pharma assets, operating expenses and Acerus Pharma free cash flow. The Acerus Pharma profit and loss statement shows revenue of $2.1M for 2018 Q2. Revenue has grown by 29.63% QoQ for TRLPF stock.

View and download details of revenue and profits for Acerus Pharma for latest & last 40 quarters.
show more
Quarterly
Annual
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q1
Acerus Pharma Revenues or Net Sales
2.1M1.62M2.1M1.9M1.45M1.27M1.81M1.65M2.14M10.41M
Cost Of Goods Sold (COGS)--1.34M-----2.22M-
Acerus Pharma Gross Profit
---1.23M--1.1M-8.39M9.59M
Research & Development Expense----------
Selling General & Admin Expense--3.07M1.79M1.48M1.62M1.6M1.44M1.46M-
Income Before Depreciation Depletion Amortization---3.25M-0.92M-1.07M-1.71M-0.88M-0.83M6.53M8.13M
Depreciation Depletion Amortization----------
Non Operating Income----1.3M-0.78M-0.24M----1.75M
Interest Expense----------
Acerus Pharma Pretax Income
---2.34M-2.32M-1.93M-2.07M-0.31M-0.95M6.61M6.06M
Provision for Income Taxes----------
MinorityInterest----------
Investment Gains Losses----------
Other Income----------
Income Before Extraordinaries & Disc Operations-6.41M-4.45M-2.11M-2.33M-1.94M-2.08M-0.31M-0.95M6.46M5.92M
Extraordinary Items & Discontinued Operations----------
Acerus Pharma Profit/ Loss (Net Income)
-6.41M-4.45M-2.11M-2.33M-1.94M-2.08M-0.31M-0.95M6.46M5.92M
Average Shares used to compute Diluted EPS213.68M213.13M213.12M213.12M213.12M213.12M209.19M213.12M215.19M206.06M
Average Shares used to compute Basic EPS213.68M213.13M213.12M213.12M213.12M213.12M209.19M213.12M209.49M200.87M
Income Before Nonrecurring Items-6.41M-4.45M-2.11M-2.33M-1.94M-2.08M-0.31M-0.95M6.46M5.92M
Income from Nonrecurring Items----------
Acerus Pharma Earnings Per Share Basic Net
-0.03-0.02-0.01-0.01-0.01-0.010.000.000.030.03
Acerus Pharma Earnings Per Share Diluted Net
-0.03-0.02-0.01-0.01-0.01-0.010.000.000.030.03
EPS Diluted Before Nonrecurring Items-0.03-0.02-0.01-0.01-0.01-0.010.000.000.030.03
Preferred Dividends Acc Pd----------
Dividends Common0.000.000.00-------
Dividend Per Share Common0.000.000.000.000.000.000.000.000.000.00
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

Click here to view our Antares Pharma financial analysis

Before investing one should read a report on Acerus Pharma stock analysis. It helps to look at the following income statement items:

  • Revenue: The money received by selling of goods or services comes under this line item. A QoQ growth - See: Acerus Pharma revenue chart, implies that the company is growing. It has been the case with Acerus Pharma. One must look at stocks with increasing revenues, and stay away from stocks whose revenues or sales are declining.
  • Bottom line: The bottomline or the net income figure is arrived at by deducting all expenses from the topline which in this case is $-6.41M for TRLPF stock. An improving bottomline implies that the company is growing its profits.

The income statement is also called the profit and loss statement. Apart from the TRLPF income statement, one can check the Acerus Pharma historical stock prices to check how the price has moved with time.

Acerus Pharma Income Statement - Key Financial Ratios

PS Ratio (price sales ratio)
5.84
Operating Margin
0
Dividend Yield
0%